
    
      This trial is a prospective, randomized, multi-center, open label, noninferiority trial.
      Patients undergoing PCI with DES will be eligible. After successful PCI with DES, all
      eligible patients will be randomized either to clopidogrel monotherapy or to aspirin plus
      P2Y12 antagonist following 3-month of DAPT.
    
  